PA
ORC

PharVision Advisers’s Orchid Island Capital ORC Stock Holding History

PharVision Advisers’s Portfolio ORC Stock Details ORC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,180
Closed -$128K – 108
2026
Q1 		$128K Sell
18,180
-31,357
-63% -$237K 1.3% 25
2025
Q4 		$357K Buy
49,537
+15,812
+47% +$115K 0.18% 183
2025
Q3 		$236K Sell
33,725
-13,770
-29% -$97.9K 0.13% 371
2025
Q2 		$333K Buy
47,495
+26,647
+128% +$185K 0.48% 61
2025
Q1 		$157K Buy
+20,848
New +$171K 0.22% 226

Other funds holding ORC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Mirae Asset Global ETFs Holdings
Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $83.9B AUM 60.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PharVision Advisers's ORC Position: Q2 2026 in Review

PharVision Advisers sold out of Orchid Island Capital (ORC) in Q2 2026, closing a stake of 18,180 shares — an estimated $128K sold.

PharVision Advisers first reported a position in ORC in Q1 2025 and held it in 5 quarters. The position peaked at $357K in Q4 2025. 202 funds tracked by Wall St. Rank hold ORC as of Q2 2026.

  • PharVision Advisers reported no remaining Orchid Island Capital position as of Q2 2026 after selling out during the quarter.
  • PharVision Advisers sold 18,180 Orchid Island Capital shares in Q2 2026, an estimated $128K.
  • PharVision Advisers first reported a position in Orchid Island Capital in Q1 2025 and held it in 5 quarters.
  • PharVision Advisers's Orchid Island Capital position peaked at $357K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Orchid Island Capital as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.